Ex-HHS Secretary Tommy Thompson adds another biotech to his resume; Medigene OK’d for first TCR clinical trial

→ Former HHS Secretary Tommy Thompson is expanding his biotech resume. Thompson has signed as a board member at New York-based Tyme Technologies, which is working on a pipeline of cancer therapies. Thompson is also chairman of TherapeuticsMD, which recently won a reversal of the FDA’s decision to reject its lead therapy and permit a full review of its marketing application.

Medigene AG has gained a regulatory green light to begin the first Phase I/II study of its TCR-modified T cell therapy MDG1011. “With our specific study design, we are able to evaluate our T cell therapy simultaneously in various diseases and to generate data in three hematological indications in parallel,” said Kai Pinckernell, the CMO at Medigene.

→ Bloomberg reports that J&J is scouting for potential buyers of its sterilization products division, which could be worth up to $2 billion.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->